Global Liquid Biopsy Market, By Product ( Assay Kits, Instruments, Service), By Application ( Cancer Application, Non-cancer Applications ), By End User ( Reference Laboratories, Hospitals and Physician Laboratories, Academic & Research Centers, Other End Users), and opportunities and forecast 2020-2027
Liquid Biopsy Market Overview
Globally, there has been a big increase within the number of people who have cancer. The rising prevalence of cancer are often attributed to many factors, like environmental factors, tobacco consumption, infectious agents like hepatitis b and C, and life style changes. according to the who, cancer is that the second-leading reason for death globally. International Agency for research on Cancer (IARC) estimated the worldwide cancer burden, indicating that it's up to nineteen.3 million cases and 9.96 million cancer deaths in 2020. Liquid biopsy holds many advantages over ancient cancer medicine techniques—reduced value, early prognosis, medical care traditional, detection of neoplasm nonuniformity, nonheritable drug resistance, and patient comfort (by eliminating the requirement for surgery). As a result, the preference for liquid diagnostic assay can probably rise within the forecast amount, proportional to the expansion in cancer prevalence.
Companion medicine embody tests or assays supposed to help aid suppliers in creating treatment choices for patients supported the most effective response to medical care. The co-development of companion medicine with therapeutic merchandise will considerably alter the drug development method and commercialize drug candidates by yielding safer medication with increased therapeutic effectualness quickly and cost-effectively. With the enhanced demand for costly specialist therapies and safer medication, the marketplace for companion medicine has high growth potential. The growing importance of companion medicine is additionally providing growth opportunities for the liquid biopsy market.
Detecting ctDNA in liquid biopsies is technically difficult as a result of the amount of ctDNA of any given cancer mutation is also terribly low within the plasma of a cancer patient, particularly once treatment or surgery. The sampling statistics mean that in any person sample of plasma from a patient, there is also but one detectable copy of the ctDNA with the cancer mutation. this could lead to the ctDNA not being detected within the patient sample, albeit it's gift within the plasma, however at a coffee level. This results in false-negative ends up in that ctDNA isn't detected albeit it's gift and impacts the informative worth of the liquid diagnostic assay tests for cancer. In some cases, false negatives might mean that the repeat of a neoplasm isn't detected at AN early stage.
The covid-19 Impact on Liquid Biopsy Market:
|Market size available for years
|Base year considered
||Value (USD Million)
||Product, Application, End User and Region
||North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
||F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., Guardant Health, Inc., MDxHealth SA, Exact Sciences Corporation, Illumina Inc., Sysmex Inostics, Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., ANGLE plc, Menarini-Silicon Biosystems, Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Epigenomics AG, Personal Genome Diagnostics, Inc.
Like several different industries, COVID-19 badly knocked the electronic and semiconductor trade. This new event has compact nearly 230 countries in exactly a couple of weeks, leading to the forced conclusion of producing and transportation activities at intervals and across the countries. This has directly affected the expansion of the sector. It's calculable that COVID-19 to depart over USD thirty billion impacts on the physics and semiconductor trade. The arena is majorly affected thanks to transport restrictions on major physics and semiconductor staple suppliers. However, the rising want for semiconductors in many industries can supply fast market recovery over the longer-term amount. Liquid Biopsy Market Segment Overview
By Product, assay kits segment accounted for the largest share of the liquid diagnostic test market, by product & service, The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. The assay kits section accounted for the largest share of the liquid diagnostic test market in 2020. the standard purchase requirement of assay kits makes them a recurrent cost that is a key issue attributing to the growth of this section.
By Application, cancer application section accounted for the largest share within the market,The liquid biopsy market is segmented into cancer and non-cancer applications based on application. The cancer application section accounted for the largest share of the liquid diagnostic test market in 2020. Factors like the increasing prevalence of cancer and also the growing range of analysis studies on liquid biopsy for cancer applications square measure driving the growth of this segment.
By End User, reference laboratories segment accounted for the largest share within the market, The liquid diagnostic test market has been metameric into reference laboratories, hospitals and MD laboratories, tutorial & analysis centers, and different finish users. The reference laboratories section accounted for the largest share of the liquid diagnostic test market in 2020. The increasing outsourcing of liquid biopsy tests to reference laboratories is driving the growth of this segment.
Market Analysis, Insights and Forecast – By Product
· Assay Kits,
Market Analysis, Insights and Forecast – By Application
· Cancer Application
· Non-cancer Applications
Market Analysis, Insights and Forecast – By End User
· Reference Laboratories
· Hospitals and Physician Laboratories
· Academic & Research Centers
· Other End UsersLiquid Biopsy Market Regional Overview
Region-wise, in terms of regions, North America accounted for the largest share of the liquid biopsy market. the massive share of this regional section is attributed to the easy accessibility to technologically advanced instruments, highly developed healthcare systems within the U.S. and canada, and presence of the many leading national clinical laboratories.
Liquid Biopsy Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA) Liquid Biopsy Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Liquid Biopsy are highlighted below.
· In 2021, guardant Health, Inc. (US) launched its Guardant360 Response test that detects changes in circulating tumor DNA (ctDNA) levels.Liquid Biopsy Market, Key Players
· F. Hoffmann-La Roche Ltd.
· Myriad Genetics, Inc.
· QIAGEN N.V.
· Thermo Fisher Scientific, Inc.
· Guardant Health, Inc.
· MDxHealth SA
· Exact Sciences Corporation
· Illumina Inc.
· Sysmex Inostics
· Bio-Rad Laboratories, Inc.
· Biocept, Inc
· NeoGenomics, Inc.
· ANGLE plc
· Menarini-Silicon Biosystems
· Vortex Biosciences, Inc.
· Exosome Diagnostics, Inc.
· Agena Bioscience, Inc.
· MedGenome Inc.
· Epigenomics AG
· Personal Genome Diagnostics, Inc.
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Liquid Biopsy market during the forecast period?
A. Liquid Biopsy market is expected to record a CAGR of ~ xx% during the forecast period
Q2. Which segment is projected to hold the largest share in the Liquid Biopsy Market?
A. Assays kits segment is projected to hold the largest share in the Liquid Biopsy Market
Q3. What are the driving factors for the Liquid Biopsy market?
A. The rising prevalence of cancer are often attributed to many factors, is key factors that boost the growth of the Liquid Biopsy market progressively.
Q4. Which Segments are covered in the Liquid Biopsy market report?
A. Product, Application, End User and Region, these segments are covered in the Liquid Biopsy market report.
Q5. Which are the prominent players offering Liquid Biopsy ?
A. F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., Guardant Health, Inc., MDxHealth SA, Exact Sciences Corporation, Illumina Inc., Sysmex Inostics, Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., ANGLE plc, Menarini-Silicon Biosystems, Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Epigenomics AG, Personal Genome Diagnostics, Inc.